Clemastine fumarate shows promise as a remyelinating agent for multiple sclerosis

This phase 2 clinical trial (ReBUILD) evaluated the use of clemastine fumarate—a first-generation antihistamine capable of inducing oligodendrocyte differentiation—as a remyelinating therapy for patients with multiple sclerosis.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553